Valeant 2 29 stock price

Analysts Hail Pearson's Return To Valeant As Patent Challenges From Allergan Looms

Patent challenges, restatement of earnings and lack of forward looking guidance are all greeting Michael Pearson, Valeant's former Chairman and CEO, who is coming back to the firm today. Pearson's job responsibilities are being clipped, with his chairman title being an oversight role at Valeant to be executed by Robert A. Ingram, a former executive of GlasxoSmithKline, the company announced over the weekend.


Analysts encouraging on Pearson's . . .

SORRY!

This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email support@valuewalk.com and we will get back to you as quick as humanly possible


Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers


0